Document 0640
 DOCN  M94A0640
 TI    Potential molecular competitors for HIV.
 DT    9412
 AU    Pieczenik G; Cook College, Rutgers University, New Brunswick, NJ 08903.
 SO    Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:64 (abstract no. TB5).
       Unique Identifier : AIDSLINE ASHM5/94349015
 AB    The phenotype of clinically non-pathogenic strains of HIV-1 do not
       differ dramatically from the clinical picture of pathogenic strain of
       HIV-1. A differential diagnosis of a clinical infection with a
       non-pathogenic strain is the observation of infectious hypo virulence.
       Infectious hypo virulence is an infection of a partner or a cluster of
       partners that shows an amelioration of symptoms or no AIDS symptoms over
       time. The increased appearance of competitive transdominant
       non-pathogenic strains may be the mechanism for ending an epidemic. The
       calculated frequency of finding a non-pathogenic strain in a population
       is related to the target size for clinical pathogenicity divided by the
       size of the HIV-1 genome. A polio-type target size for HIV pathogenicity
       (1 in 22 nucleotides) gives a frequency of 1 in 400 to 600 HIV-1
       positive individuals carrying a non-pathogenic strain. This polio type
       model also predicts that an individual carrying a competitive strain
       will, also, have had at least 400-600 different HIV-1 infected partners.
       The frequency of CD4+ T-Lymphocytopenia suggest that 1 in 9,500
       individuals carry the second 22 nucleotide sequence, which is only
       responsible for cytopathology, and none of the rest of the HIV-1 genome.
 DE    Base Sequence/GENETICS  Cytopathogenic Effect, Viral/GENETICS  DNA,
       Viral/GENETICS  Human  HIV Infections/*MICROBIOLOGY
       HIV-1/*GENETICS/PATHOGENICITY  Virulence/GENETICS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).